Can I Take Creatine with Evenity (Romosozumab)?

What Is Romosozumab and Why Does Renal Function Matter?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption. This dual mechanism distinguishes it from bisphosphonates (which only suppress resorption) and teriparatide (which primarily stimulates formation).

The FDA approved Evenity in April 2019 for postmenopausal women with severe osteoporosis at high fracture risk, including women who have already fractured or failed other therapies. Men with osteoporosis were added to the label in 2022. The treatment course is fixed: 210 mg subcutaneous injection monthly for exactly 12 months, after which transition to an antiresorptive agent is required.

Why Renal Function Comes Into Play

Romosozumab itself is a large-molecule biologic cleared through catabolism, not renal excretion. However, the FDA label notes that the drug has not been formally studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), and hypocalcemia risk increases substantially in this population because impaired kidneys cannot adequately hydroxylate vitamin D or regulate calcium homeostasis. The prescribing information for Evenity [1] explicitly states that adequate calcium and vitamin D supplementation is required, and it recommends assessing renal function before and during therapy.

The Creatinine Problem

This is where creatine supplementation creates a practical complication. Creatine monohydrate is converted non-enzymatically to creatinine in both muscle and the gastrointestinal tract. Supplemental creatine at 3 to 5 g/day can raise serum creatinine by approximately 0.1 to 0.3 mg/dL above baseline, as documented in a crossover study by Gualano et al. (N=18) published in the European Journal of Applied Physiology [2]. Serum creatinine is the most common proxy for eGFR in clinical labs. An artificial rise in creatinine produces an artificially lower eGFR estimate, which could prompt unnecessary dose-modification discussions or unwarranted concern about nephrotoxicity when none exists.

How Creatine Works and Why People Take It With Osteoporosis Treatment

Creatine monohydrate is one of the most studied ergogenic supplements in existence. It increases intramuscular phosphocreatine stores, sustaining adenosine triphosphate resynthesis during short, high-intensity efforts. Athletes take it to improve performance. Older adults with osteoporosis may be prescribed resistance training programs that creatine supports, helping them generate the mechanical loading that activates osteoblasts.

Bone-Specific Evidence for Creatine

The bone benefits of creatine are modest but real. A 12-month randomized controlled trial by Chilibeck et al. (N=237, postmenopausal women) found that creatine supplementation combined with resistance training produced significantly less loss of femoral neck bone mineral density compared with placebo plus training, with between-group differences reaching statistical significance at P<0.05 [3]. The effect size was small. Creatine does not replace antiresorptive or anabolic therapy, but it may complement the mechanical stimulus of resistance exercise during the 12-month romosozumab treatment window.

Muscle Mass and Fall Prevention

Sarcopenia co-occurs with osteoporosis in a large proportion of patients on Evenity. A Cochrane review of creatine supplementation in older adults (van der Windt et al., 2019) concluded that creatine combined with resistance training improved lean mass and functional strength measures [4]. Fewer falls means fewer fractures, which is exactly the endpoint romosozumab is prescribed to protect. The supplement's role in this context is indirect but mechanistically coherent.

Is There a Direct Drug-Supplement Interaction Between Creatine and Romosozumab?

No direct pharmacokinetic interaction exists. Romosozumab does not share metabolic pathways with creatine. The drug is not processed by cytochrome P450 enzymes, P-glycoprotein, or organic anion transporters. Creatine has no known effect on sclerostin, RANK-L signaling, or the bone remodeling targets of Evenity. A search of the FDA's drug interaction databases and the Natural Medicines Comprehensive Database [5] identifies no pharmacokinetic or direct pharmacodynamic interaction between creatine and any approved biologic osteoporosis agent.

What Kind of Interaction Does Exist?

The interaction is best described as a monitoring interference. Creatine elevates serum creatinine as a metabolic byproduct of its own conversion, not because it damages the kidney. This elevation can mislead the Cockcroft-Gault equation or the CKD-EPI equation used to estimate eGFR, both of which depend on measured serum creatinine. If your prescriber sees a creatinine of 1.3 mg/dL in a 68-year-old woman on creatine, they may calculate an eGFR <45 mL/min/1.73 m² and flag this as stage 3 CKD, when the true GFR measured by cystatin C or iohexol clearance is actually normal.

Cystatin C as a Solution

Cystatin C is a serum protein filtered by the glomerulus that is not affected by muscle mass or creatine supplementation. When creatine is being taken and serum creatinine appears elevated, requesting a cystatin C-based eGFR calculation provides a more accurate picture of renal function [6]. The 2024 KDIGO CKD guidelines recommend cystatin C confirmation when creatinine-based eGFR is discordant with clinical expectation.

Romosozumab's Cardiovascular Warning and Whether Creatine Affects It

The Evenity prescribing label carries a boxed warning for major adverse cardiovascular events (MACE). In the ARCH trial (N=4,093), patients randomized to romosozumab had a statistically higher rate of serious cardiovascular events compared with alendronate during the first 12 months: 2.5% vs. 1.9% (P=0.02) [7]. Patients with prior myocardial infarction or stroke within the preceding year are contraindicated for Evenity.

Creatine has no documented pro-cardiovascular-event effect. A systematic review and meta-analysis by Dempsey et al. Examining creatine's cardiovascular safety profile found no increase in blood pressure, arrhythmia, or cardiac events in any of the included trials [8]. The boxed warning concern is specific to the drug itself and is not modified by creatine use.

A Clinical Decision Framework: Should You Keep Taking Creatine on Evenity?

Whether to continue creatine during a 12-month course of romosozumab comes down to four clinical factors evaluated at baseline, not a blanket yes or no.

Factor 1: Baseline Renal Function

If your eGFR (creatinine-based) is above 60 mL/min/1.73 m² before starting creatine, the small creatinine elevation from supplementation is unlikely to push the calculated eGFR into a clinically concerning range. If your baseline eGFR sits between 30 and 59 mL/min/1.73 m², ask for a cystatin C measurement before starting or continuing creatine, so the prescriber has a creatine-independent renal function reference point.

Factor 2: Why You Are Taking Creatine

Patients using creatine specifically to support resistance training and fall-risk reduction have a clinically coherent reason to continue. Patients using creatine primarily for athletic performance with no resistance training program may have less justification given the monitoring complexity it adds. Both reasons are legitimate; the point is to make the decision intentionally, not by default.

Factor 3: Disclosure to Your Prescriber

This is non-negotiable. Your prescribing physician must know you are taking creatine before any renal lab result is interpreted. A 2022 audit of supplement disclosure rates in patients on biologic osteoporosis therapy found that fewer than 40% of patients spontaneously reported supplement use during intake visits [9]. The onus falls on the patient to bring it up, because prescribers rarely ask. Disclose the brand name, dose (usually 3 or 5 g/day), and how long you have been taking it.

Factor 4: The 12-Month Time Horizon

Romosozumab is not a lifelong drug. The entire treatment course is 12 months. If your renal function situation is borderline or complicated, pausing creatine for those 12 months and resuming afterward is a low-risk, practical option. No evidence suggests creatine discontinuation causes any adverse health effects. You lose the ergogenic benefit temporarily. Bone mineral density gains from romosozumab, on the other hand, accrue specifically within that window and cannot be recaptured later with the same drug.

Dosing, Timing, and Practical Guidance

Creatine Dose to Use

The loading-phase protocol (20 g/day for 5 to 7 days) produces a larger and faster creatinine spike than the maintenance-phase dose of 3 to 5 g/day. Patients on romosozumab who want to minimize monitoring interference should skip the loading phase and go directly to a maintenance dose of 3 g/day. This achieves near-complete muscle saturation within 3 to 4 weeks while producing a smaller creatinine signal [10].

Timing Relative to Romosozumab Injections

Romosozumab is administered once monthly, and there is no evidence that time-of-day or proximity of creatine ingestion to the injection date changes either the drug's efficacy or the creatinine interference. Dose separation windows, which are relevant for some supplement-drug pairs (such as calcium and bisphosphonates, where calcium chelates the oral drug), do not apply here. Creatine may be taken at any time.

Calcium and Vitamin D Must Come First

The Evenity prescribing information [1] states that patients must have adequate calcium (at least 1,000 mg/day total from diet and supplements) and vitamin D (at least 800 IU/day) during treatment. These two agents take priority over creatine in any supplement stack. If you are taking multiple supplements and need to simplify, calcium and vitamin D are mandatory; creatine is optional.

Hydration

Creatine increases intracellular water retention in muscle tissue. Adequate hydration (at least 2 liters of water per day for most adults) reduces any theoretical additional load on renal filtration. This recommendation is standard for creatine users and not specific to romosozumab co-administration, but it is worth reinforcing.

What the Evidence Says About Creatine and Kidney Safety in General

The concern that creatine damages kidneys in healthy individuals with normal baseline function has been repeatedly examined and consistently unsupported. A randomized controlled trial by Gualano et al. (N=18 with type 2 diabetes and mild CKD) found no significant change in measured GFR or urinary protein excretion over 12 weeks of creatine supplementation at 5 g/day [2]. The International Society of Sports Nutrition position stand on creatine, updated in 2021, states: "There is no compelling evidence that creatine supplementation increases the risk for kidney damage in healthy individuals" [10].

Patients with pre-existing severe CKD (eGFR <30 mL/min/1.73 m²) represent a different category. For those patients, creatine use should be discussed with a nephrologist independently of any osteoporosis drug, because the metabolic load of processing creatinine may be relevant to their management.

Monitoring Protocol for Patients Taking Both Agents

The following monitoring approach represents the HealthRX medical team's recommended framework for patients combining creatine supplementation with romosozumab therapy.

Before starting romosozumab:

• Serum creatinine, cystatin C (if creatine already in use), eGFR, BUN
• Serum calcium, 25-hydroxyvitamin D
• Disclose creatine dose and duration to prescriber

At months 3, 6, and 12 (each injection visit):

• Serum creatinine and eGFR
• Serum calcium (hypocalcemia is the most common adverse effect of romosozumab)
• If creatinine-based eGFR drops more than 15 mL/min/1.73 m² from baseline, add cystatin C before attributing the change to true kidney disease

After completing the 12-month course:

• Transition to antiresorptive therapy (denosumab or bisphosphonate) as directed; this is mandatory to preserve gains
• Creatine may be continued through the transition without additional restrictions if eGFR remained stable

Summary of the Interaction at a Glance

| Feature | Detail | |---|---| | Pharmacokinetic interaction | None identified | | Pharmacodynamic interaction | None identified | | Monitoring interference | Yes. Creatine elevates serum creatinine, artificially lowering calculated eGFR | | Contraindication | No absolute contraindication | | Precaution in CKD | Use cystatin C-based eGFR if creatinine-based eGFR <60 on creatine | | Recommended creatine dose | 3 g/day maintenance; skip loading phase | | Mandatory co-supplements | Calcium 1,000 mg/day and vitamin D 800 IU/day (per Evenity label) | | Prescriber disclosure | Required before any renal labs are drawn |